Director/PDMR Shareholding
Updated : 07:06
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Director/PDMR Shareholding
Intelligent Ultrasound Group plc (AIM: MED), the ultrasound artificial intelligence (AI) software and simulation company, announces the following director share transactions.
The Company announces that Ian Whittaker, a Person Discharging Managerial Responsibilities of the Company ("PDMR"), transferred 374,982 Ordinary Shares in the Company for nil consideration on the 4th March 2020 to a nominee account of which he is the beneficial owner.
Following this transaction, Ian Whittaker's interest and that of his persons closely associated in Ordinary Shares remains unchanged at 374,982 Ordinary Shares of 1p representing 0.17% of the total issued share capital of the Company.
This notification relates to a transaction notified in accordance with the Market Abuse Regulation, further details below:
NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Ian Whittaker |
2 | Reason for the notification | |
a) | Position/status | Chief Operating Officer, PDMR |
b) | Initial notification/amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Full name of the entity | Intelligent Ultrasound Group plc |
b) | Legal entity identifier code |
|
4 | Details of the transaction(s) | |
a) | Description of the financial instrument, type of instrument | Ordinary shares in Intelligent Ultrasound plc with a nominal value of 1 pence each |
b) | Identification Code |
|
c) | Nature of the transaction | Transfer to a nominee account |
d) | Currency | GBP - British pound |
e) | Price(s) and Volume(s) | N/A |
f) | Aggregated information - Price - Volume - Total | N/A |
g) | Date of transaction | 4th March 2020 |
h) | Place of transaction | Off market |
Intelligent Ultrasound Group plc | |||
Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 | ||
|
| ||
Cenkos Securities - Nominated Advisor and broker | Tel: +44 (0)20 7397 8900 | ||
Giles Balleny / Cameron MacRitchie (Corporate Finance) |
| ||
Michael Johnson / Julian Morse (Sales) |
| ||
|
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com | ||
Anna Dunphy / Paul McManus | Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893 | ||
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.
Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.
Simulation Division
Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.